Efficacy of Cevostamab Increases With Higher Doses in Heavily Pretreated Multiple Myeloma
December 14th 2021
Cycle 1 double step-up dosing with cevostamab demonstrated encouraging activity with effective cytokine release syndrome mitigation in patients with heavily pretreated relapsed/refractory multiple myeloma, supporting further development of the dual-targeted bispecific antibody.